Why AbbVie’s $10.9 Billion Bet on Apogee Could Reshape the Eczema Market

North Chicago, Monday, 22 June 2026.
AbbVie’s $10.9 billion acquisition of Apogee Therapeutics isn’t just its largest deal since 2019—it’s a high-stakes play to dominate the eczema market. The prize? Zumilokibart (APG777), a Phase 2b monoclonal antibody with the potential to outperform rivals like Eli Lilly and Regeneron. With a 60% premium for Apogee’s shares, AbbVie is betting big on a drug that could redefine treatment for millions. But the move also signals a broader trend: Big Pharma’s rush to snap up early-stage biotechs before patent cliffs hit. Will this gamble pay off, or is AbbVie overpaying for unproven science?